Technavio analyzes that the Herpes Zoster Therapeutics Market is expected to grow at a CAGR of 13.7% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 5069.8 million.There are various factors that contribute to the growth of the market. The herpes zoster, or shingles, market is experiencing significant growth due to the increasing prevalence of this viral infection. According to recent studies, the global incidence rate of herpes zoster is on the rise, particularly among older adults and individuals with weakened immune systems. This trend is driving demand for effective therapeutics to manage the painful symptoms and prevent complications associated with the disease. The market for herpes zoster therapeutics is anticipated to expand at a robust pace in the coming years, as pharmaceutical companies invest in research and development of new treatments and vaccines.
In the realm of Herpes Zoster Therapeutics, vaccines represent a significant segment, offering proactive disease prevention. Vaccines function by administering dead or live microbial antigens to individuals prior to natural infection, thereby inducing active immunization. Post-immunization, if an individual contracts the antigen, existing antibodies generated from the vaccine facilitate rapid elimination. SHINGRIX, a non-live varicella-zoster vaccine, boasts a 90% efficacy rate in preventing shingles in individuals aged 50 and above. This vaccine's importance lies in its ability to shield against this debilitating condition, thereby reducing the burden on healthcare systems and improving overall patient wellbeing. Academic institutes continue to invest in research and development of advanced vaccines to combat Herpes Zoster and its complications.
Know which region is leading the market growth by requesting a sample report
Herpes Zoster Therapeutics Market Segmentation
As per our research findings, here are some of the key competitors that are leading the industry
Find out what is trending in the market by accessing the free PDF report
The Herpes Zoster Therapeutics Market encompasses various aspects of care, including medical devices, health economics, and patient education, for managing herpes zoster (shingles), a viral infection causing pain and neurological complications. Healthcare providers focus on antiviral therapy for cost-effective treatment and pain management. Immunology, virology, and clinical trials are crucial for vaccine efficacy and prevention. Public health initiatives prioritize data analysis, biotechnology, and treatment guidelines. Herpes zoster incidence and complications impact healthcare policy, immunosuppression, and post-herpetic neuralgia. Elderly care centers focus on patient safety, vaccine coverage, and herpes zoster diagnosis. Research institutes investigate vaccine efficacy, immunology, and health outcomes. Herpes zoster prevention and treatment rely on the immune system, and health insurance covers diagnostic tests and therapies. Molecular diagnostics, health economics, and healthcare policy address herpes zoster's impact on patient safety and healthcare costs. Pain reduction is a significant focus for herpes zoster treatment, with ongoing research in neurological complications and immunosuppression.
The Herpes Zoster Therapeutics Market is a significant segment of the global pharmaceuticals industry, encompassing companies involved in the research and development (R&D) or production of both generic and non-generic drugs, as well as veterinary drugs. According to Technavio, the global pharmaceuticals market size is determined by the consolidated revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing population of immunocompromised patients and the rising prevalence of Varicella-zoster virus (VZV) infections, particularly among the elderly. Additionally, the growing demand for disease management solutions, including laboratory testing and serological testing, will further fuel market expansion. With an aging population, the number of individuals susceptible to Herpes Zoster (shingles) is projected to increase substantially, particularly in regions such as Europe and the US, where the population over 60 years old is expected to reach nearly one-quarter by 2030 and 2050, respectively. This demographic shift will create a significant demand for effective therapeutic solutions to manage the symptoms and complications of Herpes Zoster, contributing to the market's continued growth.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
